NCT01450319View on ClinicalTrials.gov

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Colorectal Neoplasms
Interventions
DRUG

Cetuximab

Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.

Trial Locations (9)

Unknown

Research Site, A Coruña

Research Site, Asturias

Research Site, Barcelona

Research Site, Córdoba

Research Site, Madrid

Research Site, Navarra

Research Site, Santiago de Compostela

Research Site, Seville

Research Site, Valencia

All Listed Sponsors
collaborator

Merck, S.L., Spain

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01450319 - Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype | Biotech Hunter | Biotech Hunter